Swedish Doubts About Avodart Sink Prostate Cancer Prevention Claim
This article was originally published in The Pink Sheet Daily
GlaxoSmithKline halts global pursuit of a prostate cancer risk reduction claim for its 5-alpha reductase inhibitor dutasteride after Swedish regulators echo FDA concerns about clinical benefit and safety.
You may also be interested in...
FDA's "complete response" letter would appear to dampen the company's most lucrative opportunity for expanding the benign prostatic hyperplasia drug's indication before entry of generic competition.
Nothing Benign About It: BPH Drugs' Bids For Prostate Cancer Risk Reduction Voted Down By Advisory Committee
Reducing the risk of low-grade prostate cancers that may not affect a patient's health isn't worth the risk of increasing the numbers of high-grade tumors, ODAC says.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.